PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32638093-1	2020	PURPOSE: This phase I study was conducted to evaluate the safety and pharmacokinetics of YM155, a potent, selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer (NSCLC).	YM 155	89-94	epidermal growth factor receptor	Homo sapiens	183-187	
33875937-0	2021	YM155 inhibits retinal pigment epithelium cell survival through EGFR/MAPK signaling pathway.	YM 155	0-5	epidermal growth factor receptor	Homo sapiens	64-68	
33875937-10	2021	YM155 down-regulated total EGFR and phosphorylated external signal-regulated protein kinase (ERK), and it up-regulated the phosphorylation of P38MAPK and c-Jun N-terminal kinase (JNK).	YM 155	0-5	epidermal growth factor receptor	Homo sapiens	27-31	
33875937-11	2021	YM155 induced endocytosis of EGFR in ARPE-19 cell.	YM 155	0-5	epidermal growth factor receptor	Homo sapiens	29-33	
33875937-13	2021	Moreover, YM155 significantly decreased the expression of phosphorylated EGFR and ERK after treated by EGF.	YM 155	10-15	epidermal growth factor receptor	Homo sapiens	73-77	
33875937-14	2021	CONCLUSION: YM155 inhibits RPE cell survival, the cell proliferative and migrative capacity, and it effectuates a small amount of cell death through the EGFR/MAPK signaling pathway.	YM 155	12-17	epidermal growth factor receptor	Homo sapiens	153-157	
32001757-5	2020	We found that YM155 reduces EGFR expression in TNBC cells, shedding light on its potential mechanism of synergism with afatinib.	YM 155	14-19	epidermal growth factor receptor	Homo sapiens	28-32	
28787001-0	2017	YM155 as an inhibitor of cancer stemness simultaneously inhibits autophosphorylation of epidermal growth factor receptor and G9a-mediated stemness in lung cancer cells.	YM 155	0-5	epidermal growth factor receptor	Homo sapiens	88-120	
30315932-0	2018	YM155 sensitizes non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitors through the mechanism of autophagy induction.	YM 155	0-5	epidermal growth factor receptor	Homo sapiens	53-57	
30315932-4	2018	In this study, we showed that YM155 markedly enhanced the sensitivity of erlotinib to EGFR-TKI resistant NSCLC cell lines H1650 (EGFR exon 19 deletion and PTEN loss) and A549 (EGFR wild type and KRAS mutation) through inducing autophagy-dependent apoptosis and autophagic cell death.	YM 155	30-35	epidermal growth factor receptor	Homo sapiens	86-90	
30315932-4	2018	In this study, we showed that YM155 markedly enhanced the sensitivity of erlotinib to EGFR-TKI resistant NSCLC cell lines H1650 (EGFR exon 19 deletion and PTEN loss) and A549 (EGFR wild type and KRAS mutation) through inducing autophagy-dependent apoptosis and autophagic cell death.	YM 155	30-35	epidermal growth factor receptor	Homo sapiens	129-133	
30315932-4	2018	In this study, we showed that YM155 markedly enhanced the sensitivity of erlotinib to EGFR-TKI resistant NSCLC cell lines H1650 (EGFR exon 19 deletion and PTEN loss) and A549 (EGFR wild type and KRAS mutation) through inducing autophagy-dependent apoptosis and autophagic cell death.	YM 155	30-35	epidermal growth factor receptor	Homo sapiens	129-133	
30315932-10	2018	Therefore, combination of YM155 and erlotinib offers a promising therapeutic strategy in NSCLC with EGFR-TKI resistant phenotype.	YM 155	26-31	epidermal growth factor receptor	Homo sapiens	100-104	
29413056-11	2018	Our results suggested that YM155, an ILF3 inhibitor, has the potential for utilization in cancer therapy against EGFR-positive lung cancers.	YM 155	27-32	epidermal growth factor receptor	Homo sapiens	113-117	
28787001-8	2017	Notably, YM155 inhibited tumorsphere formation by blocking the autophosphorylation of EGFR and the EGFR-G9a-mediated stemness pathway.	YM 155	9-14	epidermal growth factor receptor	Homo sapiens	86-90	
28787001-8	2017	Notably, YM155 inhibited tumorsphere formation by blocking the autophosphorylation of EGFR and the EGFR-G9a-mediated stemness pathway.	YM 155	9-14	epidermal growth factor receptor	Homo sapiens	99-103	
23325792-11	2013	As with YM-155 alone, sensitivity to YM-155 and ABT-737 inversely correlated with EGFR activation status.	YM 155	8-14	epidermal growth factor receptor	Homo sapiens	82-86	
23325792-11	2013	As with YM-155 alone, sensitivity to YM-155 and ABT-737 inversely correlated with EGFR activation status.	YM 155	37-43	epidermal growth factor receptor	Homo sapiens	82-86	
23325792-0	2013	YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context.	YM 155	0-6	epidermal growth factor receptor	Homo sapiens	117-121	
22723871-0	2012	YM155 induces EGFR suppression in pancreatic cancer cells.	YM 155	0-5	epidermal growth factor receptor	Homo sapiens	14-18